Skip to content

Released Mar 14, 2024, before the open

10-K filed Mar 14, 2024, 74 days after period end · 0001558370-24-003161

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$10.49Mderived+21.7% vs Q4 2022+1.4% vs Q3 2023
Net Income-$6.04MderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$5,615,000N/M
Operating Cash Flowderived$3,595,000N/M
Free Cash Flowderived$3,345,000N/M
Margins · derived
Operating margin-53.5%−24.6 pt vs Q4 2022
Net margin-57.6%−14.2 pt vs Q4 2022

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figures
Revenue$10.49M$8.62M$8.55M$19.50M
Net Income-$6.04M-$3.74M-$6.67M$397.00K

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR